Learning Hub

< BACK Calling for Influencers: Join iPROLEPSIS as an Ambassador for Psoriatic Arthritis Feb 27, 2024 Join the iPROLEPSIS Initiative: Become an Ambassador for the iPROLEPSIS Project Join the iPROLEPSIS initiative! Calling all influencers, psoriatic arthritis warriors and health advocates to become iPROLEPSIS Ambassadors ! Our mission is to shed light upon the health-to-PsA transition through groundbreaking AI-driven analysis and cutting-edge technology. We are creating a digital health ecosystem for personalised psoriatic arthritis risk prediction and management. Are you passionate about health advocacy and psoriatic arthritis awareness? Become an iPROLEPSIS Ambassador and be a part of the change! Here is how you can make a difference as an iPROLEPSIS Ambassador: Promote the iPROLEPSIS mission Share iPROLEPSIS updates and developments Share personal stories and insights Ready to be a part of the change? Contact us at info@iprolepsis.eu , and we will provide you with more details. * Please note that this is voluntary, and no monetary compensation is offered. AI-PROGNOSIS events (8).png AI-PROGNOSIS events (8).png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search RSS News Feed

iProlepsis psoriatic arthritis project is a comprehensive multiscale model employing novel trustworthy AI-based analysis of multisource and heterogenous data. iPROLEPSIS project objectives and work packages Project aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale / multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioral) data. Project objectives iPROLEPSIS consortium works on 7 ambitious key objectives in the field of Psoriatic Arthritis (PsA). PsA inflamation drivers Discover PsA inflammation drivers through AI-driven health, environmental and omics data mining. Role of mast cells Investigate the role of mast cells and features from non-invasive skin microvascular/joint imaging in inflammatory symptoms tracking. Personalised interventions Develop ICT-based personalised interventions to sustain or even improve quality-of-life. Co-creative ecosystem Co-create the iPROLEPSIS ecosystem with key stakeholders, following ethical, inclusive and trustworthy AI principles. Digital biomarkers Develop and validate objective digital biomarkers for tracking inflammatory symptoms and disease activity. Trustwothy AI models Build trustworthy AI models for personalised PsA risk prediction, early diagnosis and high disease activity prognosis. Digital health ecosystem Develop and clinically validate the iPROLEPSIS digital health ecosystem to empower persons with/at risk of PsA and healthcare professionals. Work packages The 6 Work Packages of the project will bring together various and complementary expertise from consortium partners. WP1 WP2 WP3 WP4 WP5 WP6 Work Package 1: Management and coordination WP1 is dedicated to project management and coordination aiming to enable a smooth project workflow; Ensure optimal contractual, administrative, financial, scientific, technical, IP and innovation management; Assure project quality and safeguard ethics, regulatory compliance and proper data management. Work Package 2: Knowledge mining, foundation and participatory design WP2 aims to create a foundational body of knowledge concerning PsA, associated conditions and inflammation; Identify, retrieve and curate datasets relevant to R&D activities of the project; Identify user needs and effectively engage with key stakeholders for steering research questions and co-creating the iPROLEPSIS digital care tools; Establish and monitor practices for ensuring adherence of iPROLEPSIS AI-driven components to trustworthy AI principles. Work Package 3: Research on PsA inflammation drivers and monitoring WP3 is dedicated to identify drivers related to PsA and associated inflammation leveraging new and existing multi-source health relevant data; Develop smartphone/wearable-based digital biomarkers (dBMs) for assessing PsA inflammatory symptoms; Shed light on changes in the joints and skin microvasculature related to PsA and the role of mast cells in associated inflammation; Through data fusion, develop a multiscale/multifactorial PsA model, emphasising on the prediction of the transition of high-risk individuals and PsO patients to PsA and of PsA patients to advanced inflammatory state. Work Package 4: Development of the iPROLEPSIS digital health ecosystem for personalised preventive care WP4 will technically specify the iPROLEPSIS ecosystem and set up a robust data management infrastructure and DevOps/MLOps platforms; Through an agile approach, develop the iPROLEPSIS minimum viable products (MVPs) for personalised PsA care including: 1) the patient app incorporating (dBM-based)PsA monitoring, knowledge, targeted interventions and tailored AI-driven lifestyle recommendations, 2) the serious gaming suite for health and wellness, 3) the app for HCPs allowing them to remotely monitor patients and view predictions on their course. Work Package 5: Clinical studies WP5 will develop the study protocols and carry out the process for their timely approval by concerned bodies; Set up a system for coordinating recruitment and efficiently managing clinical data and reporting; Organise and conduct four clinical studies: two multicentre prospective cohort studies for discovery and validation of PsA inflammation drivers and digital biomarkers, one observational study on PsA and changes in the joints and skin microvasculature, and one multicentre proof-of-concept randomised controlled trial (RCT) evaluating the effectiveness of the iPROLEPSIS digital care tools. Work Package 6: Dissemination, communication and exploitation WP6 will maximise visibility of the project and its outcomes and facilitate knowledge exchange while engaging a wide network of stakeholders; Develop PsA-related educational content; Set out a roadmap for regulatory approval of the iPROLEPSIS digital tools; Perform a thorough socio-economic/market analysis and develop concrete joint/individual exploitation plans. PROJECT VISION

< BACK Insights from iPROLEPSIS 4th Plenary meeting Jul 3, 2024 iPROLEPSIS Plenary Meeting 2024 Recap The 4th iPROLEPSIS plenary meeting took place on 1-2 July 2024 in Munich, Germany, drawing partners from across Europe. The focus was on discussing progress updates and planning future actions towards developing a novel personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). Agenda included: WP overviews, updates and planning next steps General Assembly & External Advisory Board sessions Workshop on : - IDBV (Inflammation digital biomarkers validation study) study: Overview of outcomes, data collection decisions, next steps; - PPIDC (Prevention of PsA inflammation through digital care: an intervention study) study: Objectives, cohort characteristics, study design. WP3 research activities and upcoming deliverables; - iPROLEPSIS ecosystem co-creation, usage scenarios identification, requirements definition; - Serious games co-creation: Introduction to iPROLEPSIS Games app, demonstrations, interactive feedback session. Special Acknowledgment: Gratitude to our patient partners who joined the Serious Games co-creation workshop online and provided valuable insights, ensuring our solutions are truly patient-centric. 1/10 PREVIOUS NEXT

< BACK Can ChatGPT provide appropriate meal plans for NCD patients? May 30, 2024 Assessing ChatGPT's Capability to Generate Personalised Meal Plans for Managing Non-Communicable Diseases Dietary habits significantly affect health conditions and are closely related to the onset and progression of non-communicable diseases (NCDs). Consequently, a well-balanced diet plays an important role in lessening the effects of various disorders, including NCDs. Several artificial intelligence recommendation systems have been developed to propose healthy and nutritious diets. Most of these systems use expert knowledge and guidelines to provide tailored diets and encourage healthier eating habits. However, new advances in large language models such as ChatGPT, with their ability to produce human-like responses, have led individuals to search for advice in several tasks, including diet recommendations. This study aimed to determine the ability of ChatGPT models to generate appropriate personalized meal plans for patients with obesity, cardiovascular diseases, and type 2 diabetes. Read the full publication: https://zenodo.org/records/13143043 1/1 PREVIOUS NEXT

< BACK Highlights from IEEE EMBC 2024 Sep 5, 2024 Showcasing AI-Based Solutions for Psoriatic Arthritis Care Our project partner, PLUX Biosignals, participated in the 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), held in Orlando, Florida, USA, from July 15-19, 2024. During this prestigious event, PLUX presented the innovative work of the iPROLEPSIS project, which focuses on developing a novel, personalised digital care ecosystem for individuals with psoriatic arthritis. The world's largest international biomedical engineering conference, IEEE EMBC 2024 featured an extensive range of scientific tracks covering cutting-edge research and innovations in biomedical engineering and healthcare technology. Topics included women and children's health, translational clinical research, technology transfer, entrepreneurship, and biomedical engineering education. This event provided a valuable platform for showcasing the potential of AI-based solutions in improving care for psoriatic arthritis patients and highlighted the role of digital tools in revolutionizing personalised healthcare. 1/2 PREVIOUS NEXT

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

< BACK iPROLEPSIS presented at PhD DEI 2023 Nov 13, 2023 Highlights from PhD DEI 2023 Organised by the Universidade de Lisboa (the Instituto Superior Técnico), the PhD DEI 2023 event on 10 November 2023 served as a platform for introducing new PhD students to the Department of Engineering and Informatics (DEI). The event fostered an environment of knowledge-sharing and collaboration among students from the Doctoral Program in Computer Science and Engineering and the Doctoral Program in Digital Media. One of the standout presentations at PhD DEI 2023 was the poster presentation on the iPROLEPSIS Exergames. This presentation, delivered by Bárbara Ramalho, a PhD student from the FMH-ULisboa team, highlighted the general concepts and objectives of the iPROLEPSIS project. The iPROLEPSIS Exergames were developed through a co-design process, emphasizing collaborative and innovative approaches to game design aimed at promoting physical activity and health. Read more: We now know the audience's favorite posters from PhD DEI 2023! - Departamento de Engenharia Informática (DEI) ( ulisboa.pt ) 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Games Presented at HiTech Program in Lisbon Jun 27, 2025 FMH/IST-ULisboa team showcased the project’s serious games to investors and health innovation experts On June 26, 2025, the iPROLEPSIS Games were presented during the final pitch session of the HiTech Program , held at the Thalia Theater in Lisbon, Portugal. Representing FMH/IST-ULisboa , Samuel Gomes , Bárbara Ramalho , and Filipa Magalhães introduced the iPROLEPSIS Games to an audience of investors and stakeholders interested in supporting innovative health solutions. This opportunity marked an important step in sharing iPROLEPSIS tools with a wider innovation and investment community. Read more about HiTech program here: https://hiseedtech.com/programs#header HiTech.jpg HiTech.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 7 Jan 28, 2025 Latest News from iPROLEPSIS Welcome to the 7th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_Jan 2025_Issue No. 7 .pdf Download PDF • 5.60MB 1/1 PREVIOUS NEXT

< BACK Digital Innovation for Psoriatic Arthritis Prevention Sep 11, 2025 An interview with iPROLEPSIS coordinators in Thessalonikeon Polis on how digital tools, wearables, and AI can help prevent psoriatic arthritis In a recent interview with Thessalonikeon Polis , Vasilis Charisis and Project Coordinator Prof. Leontios Hadjileontiadis from the Signal Processing & Biomedical Technology Unit – AUTH shared insights on the iPROLEPSIS project. The interview highlights the iPROLEPSIS project, showing how smartphones and wearables can assist in early detection and prevention of psoriatic arthritis through digital tools such as wearables, educational games, and personalised apps. It also touches on AI in healthcare, stressing its role in supporting – not replacing – healthcare professionals. Read the full article (in Greek): https://thessalonikeonpolis.gr/machi-kata-tou-parkinson-tehniti-noimosini/ iPROLEPSIS_interview.png iPROLEPSIS_interview.png 1/1 PREVIOUS NEXT

< BACK "The Kite" Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis Jul 31, 2024 Enhancing PsA Management through Innovative Breathing Exercises and Game-Based Therapy Latest research initiative under the iPROLEPSIS project: “The Kite” Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis presented at IEEE MELECON 2024. This study is part of a broader effort to develop and validate innovative digital biomarkers for managing Psoriatic Arthritis (PsA) through the Artificial Intelligence-Personalised Game Suite (AI-PGS). Abstract: Serious Games (SGs) have the potential to provide clinical care and enhance patients’ quality of life, while incorporating an element of entertainment. As part of the iPROLEPSIS Horizon Europe project, we introduce two Sensorimotor Art games designed as SGs to assist Psoriatic Arthritis (PsA) patients in managing their symptoms. These SGs provide a platform for self-expression and pain relief through engaging in rhythmic puzzle activities. The co-design process for the proposed Sensorimotor Art games followed an agile methodology, involving 14 experts (including clinicians, researchers, and game developers), to gather feedback on game requirements, storyboards, and mechanics. From the thematic analysis of the transcribed discussion, four main themes emerged, namely: Clinical value (Theme 1), Motor skills and adaptation (Theme 2), Creative engagement (Theme 3), and Feedback and future directions (Theme 4). Clinical value underlines the therapeutic benefits of Sensorimotor Art games for pain distraction and emotional well-being. Motor skills and adaptation focus on hand/finger use and adapting games for older patients. Creative engagement emphasizes fostering creativity, a positive environment, and goal achievement. Finally, feedback and future directions highlight the importance of continuous feedback and occupational therapists’ involvement in coming sessions. The development of Sensorimotor Art games lays the groundwork for digital interventions to alleviate psychological distress and improve fine motor symptoms in PsA patients. At the same time, these SGs can also provide insights to healthcare providers and policymakers for developing future digital solutions tailored to PsA patients. Read the full publication: https://zenodo.org/records/13141465 IEEE_MELECON_2024 .pdf Download PDF • 1.33MB 1/1 PREVIOUS NEXT